80 completed, 12 terminated, 9 withdrawn, 8 unknown. 32 Phase 4, 25 Phase 1, 22 Not applicable, 19 Phase 3, 18 Phase 2.
Follow Lisinopril: new trials by email Literature Review of Lisinopril trials Research Report on Lisinopril
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pharmacologic Therapies to Mitigate Radiation- Associated Heart Disease Atorvastatin and Lisinopril, Placebo - Chest Wall Tumor, Breast Cancer | Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 60 | 2026-08-12 | 2026-09-17 |
| The Effect Of Lisinopril On Polycythemia Lisinopril Tablets - Polycythemia | Phase 4 | Recruiting | Mayo Clinic | 30 | 2026-07-01 | 2026-08-21 |
| Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) Finerenone, Semaglutide, Lotensin - Chronic Kidney Disease, Type 2 Diabetes | Phase 4 | Enrolling by invitation | Baylor Research Institute | 64 | 2026-04-08 | 2026-10-13 |
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate - Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes | Not applicable | Enrolling by invitation | Enhanced Emirates Limited | 60 | 2026-03-12 | 2026-05-06 |
| OptiZ: Real World Evidence Study Zestril - Hypertension | Withdrawn | Closed Loop Medicine | 2025-03-01 | 2026-03-20 | ||
| Personalised Dose Optimisation of Zestril Supported by the Digital Blood Pressure Diary in a Primary Care Environment in England: Pragmatic Observational Pilot Study for Remote Hypertension Treatment Zestril - Uncomplicated Hypertension | Completed | Closed Loop Medicine | 20 | 2024-04-15 | 2026-03-20 | |
| A Study of Enlicitide Decanoate (MK-0616), Warfarin, and Lisinopril in Healthy Adult Participants (MK-0616-026) Warfarin, Enlicitide Decanoate, Lisinopril - Healthy | Phase 1 | Completed | Merck Sharp & Dohme LLC | 36 | 2024-04-01 | 2025-01-15 |
| A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer Lisinopril Tablets - Prostate Cancer, Radiation Toxicity | Early Phase 1 | Recruiting | University of Rochester | 30 | 2024-02-20 | 2026-07-23 |
| Treatment of Patients With Diabetic Kidney Disease lisinopril, enalapril, dapagliflozin, empagliflozin - Diabetic Kidney Disease | Not applicable | Unknown | Assiut University | 70 | 2024-01-01 | 2024-01-02 |
| Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. Corticosteroid, Renin-angiotensin sytem blockers, Sodium-glucose cotransporter 2 inhibitor - Glomerulonephritis, Immunoglobulin A Nephropathy | Phase 4 | Recruiting | Fondazione Schena | 878 | 2023-05-01 | 2025-04-02 |
| A Pilot Study: Preventing Adverse Remodelling Following Pacemaker Implantation Optimised programming, Lisinopril, Standard care - Pacemakers, Heart Failure | Phase 2 | Unknown | University of Leeds | 75 | 2022-12-01 | 2022-11-02 |
| Bioequivalence Study of Two Formulations of Lisinopril Tablet 20 mg in Healthy Volunteers Under Fasting Conditions Lisinopril tablet 20 mg, Zestril® tablet 20 mg - Bioequivalence | Phase 1 | Completed | Pharmtechnology LLC | 38 | 2021-10-06 | 2022-07-07 |
| A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia Sodium Zirconium Cyclosilicate (SZC), Placebo, Lisinopril - Renal Insufficiency, Chronic, Hyperkalemia | Phase 3 | Terminated | AstraZeneca | 1112 | 2021-09-30 | 2026-01-08 |
| Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study Biospecimen Collection, Lisinopril, Liver Ultrasonographic Elastography - Hepatocellular Carcinoma, Nonalcoholic Steatohepatitis | Phase 2 | Active not recruiting | Northwestern University | 35 | 2021-05-11 | 2026-08-14 |
| Optimal Management of HIV Infected Adults at Risk for Kidney Complications in Nigeria Lisinopril, Placebo Oral Tablet - HIV/AIDS, Albuminuria | Phase 2 | Terminated | Vanderbilt University Medical Center | 66 | 2021-04-01 | 2025-06-26 |
| Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial Carvedilol, Lisinopril, Pravastatin - Breast Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm | Phase 2 | Withdrawn | Mayo Clinic | 2020-09-01 | 2023-05-24 | |
| Coronavirus (COVID-19) ACEi/ARB Investigation Thiazide or Thiazide-like diuretics, Calcium Channel Blockers, ACE inhibitor - Hypertension, COVID-19 | Phase 4 | Suspended | National University of Ireland, Galway, Ireland | 2414 | 2020-04-30 | 2020-06-30 |
| ACEI or ARB and COVID-19 Severity and Mortality in US Veterans ACEI/ARB, Non-ACEI/ARB, ACEI - Hypertension, COVID | Completed | University of Utah | 22213 | 2020-01-19 | 2021-04-28 | |
| Clinical Bioequivalence Study on Two Lisinopril Tablets 20mg Formulations BF-Lisinopril Tablets 20mg, Zestril Tab 20mg - Healthy | Phase 1 | Unknown | Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited | 30 | 2019-10-01 | 2019-01-16 |
| Assessment of Immediate Postoperative Delirium (IPD) in Adult Patients: Incidence and Etiologic Factors Types of Anesthesia, Access of Surgery, Comorbidities - Delirium, Anesthesia; Adverse Effect | Completed | Sultan Qaboos University | 402 | 2019-01-01 | 2019-05-30 |
Showing 20 of 120. Sign in to see all of them.
Hypertension (45) · Cardiovascular Diseases (11) · Diabetes Mellitus, Type 2 (9) · Diabetes Mellitus (7) · Diabetic Nephropathies (7) · Renal Insufficiency, Chronic (7) · Heart Failure (5) · Albuminuria (4) · Coronary Disease (4) · Essential Hypertension (4) · Heart Diseases (4) · Breast Neoplasms (3) · Coronary Artery Disease (3) · Fasting (3) · Hyperkalemia (3)
GlaxoSmithKline (8) · IPCA Laboratories Ltd. (4) · Mayo Clinic (4) · Novartis (4) · AstraZeneca (3) · Forest Laboratories (3) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Brigham and Women's Hospital (2) · Closed Loop Medicine (2) · NYU Langone Health (2) · National Heart, Lung, and Blood Institute (NHLBI) (2) · Northwestern University (2) · Novo Nordisk A/S (2) · Par Pharmaceutical, Inc. (2) · Sandoz (2)
United States (69) · Canada (7) · United Kingdom (7) · India (6) · Puerto Rico (6) · Spain (6) · Germany (4) · Italy (4) · Switzerland (4) · Denmark (3) · Japan (3) · Netherlands (3) · Russia (3) · Sweden (3) · Belgium (2)
Arlene Chapman, M.D. (2) · Clifford L Ferguson, MD (2) · Dr. Suhas Khandave, M.D. (2) · Dr. Tarang Girishbhai Shah, M. D. (Pharmacology) (2) · Eric Masson, Pharm.D. (2) · Hans-Henrik Parving, MD (2) · Howard Trachtman, MD (2) · Marva Moxey-Mims, M.D. (2) · Ramon C Hermida, PhD (2) · Robert Schrier, M.D. (2) · Ronald Perrone, M.D. (2)
PMID 22470539, PMID 38682786, PMID 39356039, PMID 41903707, PMID 11128341, PMID 15851648, PMID 1647954, PMID 16651474, PMID 17533019, PMID 17846352, PMID 17978307, PMID 18000186, PMID 18227370, PMID 18539917, PMID 18676075, PMID 18698222, PMID 18974967, PMID 19001024, PMID 19073787, PMID 19407805, PMID 19571790, PMID 19571791, PMID 19898642, PMID 19926008, PMID 19932542, PMID 20061358, PMID 20061360, PMID 20215456, PMID 20228401, PMID 20228404, PMID 20427682, PMID 20571135, PMID 20587587, PMID 20594588, PMID 20883227, PMID 21051458, PMID 21310077, PMID 21366473, PMID 21606384, PMID 21617110, PMID 21663644, PMID 21676221, PMID 21852672, PMID 21884956, PMID 21953407, PMID 21958949, PMID 21969009, PMID 22019270, PMID 22049171, PMID 22179956
2015 (2), U01DK062401 (2), U01DK082230 (2), 2023 (1), 5KL2TR000370 (1), K23AG030057 (1), N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1), N01HC95182 (1), N01HC95183 (1), N01HC95184 (1), P01DK068055 (1), P20RR011104 (1)